PMID- 15867378 OWN - NLM STAT- MEDLINE DCOM- 20050615 LR - 20081121 IS - 0008-5472 (Print) IS - 0008-5472 (Linking) VI - 65 IP - 9 DP - 2005 May 1 TI - Impairment of stromelysin-1 transcriptional activity by promoter mutations in high microsatellite instability colorectal tumors. PG - 3811-4 AB - Colorectal tumorigenesis is characterized by the sequential inactivation of a series of tumor suppressor genes (microsatellite-stable tumors) and genetic or epigenetic alterations in mismatch repair genes in nonpoliposic hereditary tumours and 13% to 15% of sporadic colorectal cancer [high microsatellite instability (MSI-H) tumors]. We hypothesized a molecular mechanism for MSI-H colorectal tumors related to matrix metalloproteinase 3 (MMP-3) promoter mutations, down-regulation of MMP-3 expression, and impairment of MMP-9 activation. We have now analyzed the 2.2-kb full MMP-3 promoter to assess the mutation distribution. The mutations found are restricted to the polymorphic region that includes the zinc-binding protein (ZBP-89) binding element. To show that these alterations were the cause of the low expression of this gene, we have generated three constructs with different MMP-3 promoters (wild type and two mutants) and we have expressed them in SW480 human colorectal cells. The basal transcriptional activity of wild-type MMP-3 promoter was much higher than the mutants activity. In addition, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced transcriptional activity of wild-type MMP-3 promoter was 10-fold higher than the mutants activity. Dexamethasone inhibited the basal transcriptional activity of wild-type MMP-3 promoter and of the two mutants found in the MSI-H subgroup of colorectal tumors. Significantly, dexamethasone almost completely blunted the TPA-induced effect on wild-type MMP-3 promoter transcriptional activity and on the mutants, even below their basal activity. Our data show that mutations found in the polymorphic region of the MMP-3 promoter from MSI-H colorectal tumors impair its basal and induced transcriptional activity, which may contribute to their better clinical outcome. FAU - Moran, Alberto AU - Moran A AD - Departamento de Bioquimica y Biologia Molecular II, Facultad de Farmacia, Universidad Complutense, Madrid, Spain. FAU - Iniesta, Pilar AU - Iniesta P FAU - de Juan, Carmen AU - de Juan C FAU - Garcia-Aranda, Cristina AU - Garcia-Aranda C FAU - Diaz-Lopez, Antonio AU - Diaz-Lopez A FAU - Benito, Manuel AU - Benito M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Cancer Res JT - Cancer research JID - 2984705R RN - 0 (DNA-Binding Proteins) RN - 0 (Transcription Factors) RN - 0 (ZNF148 protein, human) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Base Sequence MH - Colorectal Neoplasms/*enzymology/*genetics MH - DNA-Binding Proteins/genetics MH - Down-Regulation MH - Enzyme Activation MH - Gene Expression Regulation, Enzymologic MH - Gene Expression Regulation, Neoplastic MH - Gene Transfer Techniques MH - Humans MH - Matrix Metalloproteinase 3/biosynthesis/*genetics MH - Matrix Metalloproteinase 9/metabolism MH - Microsatellite Repeats/genetics MH - Molecular Sequence Data MH - *Mutation MH - Plasmids/genetics MH - Promoter Regions, Genetic/genetics MH - Transcription Factors/genetics MH - Transcriptional Activation/*genetics EDAT- 2005/05/04 09:00 MHDA- 2005/06/16 09:00 CRDT- 2005/05/04 09:00 PHST- 2005/05/04 09:00 [pubmed] PHST- 2005/06/16 09:00 [medline] PHST- 2005/05/04 09:00 [entrez] AID - 65/9/3811 [pii] AID - 10.1158/0008-5472.CAN-04-4442 [doi] PST - ppublish SO - Cancer Res. 2005 May 1;65(9):3811-4. doi: 10.1158/0008-5472.CAN-04-4442.